Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Ajay Bharathan"'
Autor:
Michael Deichen, Mary Schmidt-Owens, Vanessa Navas, Kimberley Thrash, Lisvet Luceno, Venkata Naga Sreelalitapriya Duvuuri, Teresa Ayers, Richard I. Zraick, Ajay Bharathan, Ann Neville Miller, Shreya Atmakuri
Publikováno v:
Patient education and counseling. 105(5)
Objectives The purposes of this study were to investigate extent and type of jargon use among primary care providers at a university health center, to evaluate the association of jargon use with patient outcomes, and to identify differences in jargon
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6603564e828513a6d09dc45e1678523b
https://pubmed.ncbi.nlm.nih.gov/34489148
https://pubmed.ncbi.nlm.nih.gov/34489148
Publikováno v:
Scientific Reports
Scientific Reports, Vol 10, Iss 1, Pp 1-12 (2020)
Scientific Reports, Vol 10, Iss 1, Pp 1-12 (2020)
Much of the morbidity and mortality due to prostate cancer happen because of castration-resistant prostate cancer (CRPC) which invariably develops after anti-androgenic therapy. FDA-approved enzalutamide is commonly prescribed for CRPC which works by
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c1624a6c81e1d5c2bd5e667c40d0d09f
https://pubmed.ncbi.nlm.nih.gov/32313135
https://pubmed.ncbi.nlm.nih.gov/32313135
Publikováno v:
Cancer Research. 79:1275-1275
Background: Enzalutamide is an FDA-approved drug commonly prescribed for advanced prostate cancer. Enzalutamide slows down prostate tumor growth but resistant disease invariably develops which is incurable primarily because currently available therap
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d2a2b2a90b7c1e4d16605353c548ce46
https://doi.org/10.1158/1538-7445.am2019-1275
https://doi.org/10.1158/1538-7445.am2019-1275